Lightweight and environmentally friendly bags for pharmaceutical applications

By using a multilayer membrane structure with specific basis weight and gas permeability, the gas permeation barrier problem of drug bags when reducing membrane material is solved, realizing a lightweight and environmentally friendly drug bag design that extends shelf life and reduces the risk of expansion.

CN123076490APending Publication Date: 2026-11-10B BRAUN MELSUNGEN AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580026665.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-05
Filing Date
2025-04-01
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing drug pouches, while reducing membrane material, struggle to maintain a sufficient gas permeation barrier, leading to shortened shelf life and the risk of expansion, and also requiring additional outer packaging that increases weight and environmental impact.

Method used

A bag body is used, comprising a membrane with a specific basis weight and gas permeability, providing a single-layer encapsulated bag cavity, and a multi-layer membrane structure combining a support layer and a barrier layer to ensure a balance between mechanical properties and gas barrier properties, avoiding the need for outer packaging.

Benefits of technology

This technology achieves the goal of maintaining the gas permeability barrier of the drug bag without increasing weight or outer packaging, reducing material usage, minimizing environmental impact, extending shelf life, and reducing the risk of expansion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076490A_ABST
    Figure CN123076490A_ABST
Patent Text Reader

Abstract

A bag for pharmaceutical application includes a bag body enclosing a bag cavity, the bag body including at least one opening connecting the bag cavity to an ambient fluid, wherein the bag body includes a body wall, wherein the body wall includes a membrane, characterized in that the membrane has a value equal to or less than 270 g / m³ as measured according to ISO 536:2019. 2 The membrane has a weight of grammage and a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in an annual increase in gas volume, said increase not exceeding 3% of the total volume of the bag cavity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of drug containers, particularly drug bags, such as intravenous (IV) bags.

[0002] Cross-reference to related applications

[0003] Fluid medications and / or fluid nutrition are administered to patients in many different medical settings, such as intensive care, critical care, and intensive care treatment. Fluid medications and / or fluid nutrition are also administered to patients during various medical procedures, such as surgery. Fluid medications and / or fluid nutrition can be administered in different ways, such as intravenous injection, via a central venous catheter (or central line), via epidural, or via subcutaneous injection.

[0004] For these applications, drug containers are used. For example, in the case of intravenous administration of liquid medications and / or liquid nutrients to a patient, intravenous (IV) containers containing said liquid medications and / or those liquid nutrients are typically used. The liquid medications and / or liquid nutrients are usually diluted or suspended in a carrier fluid, which is typically a carrier solution. IV containers typically have one or more pieces of information printed on the front and / or rear surface of the container, or permanent information including a label attached to the front and / or rear surface of the container, wherein the information identifies the IV solution contained in the IV container. The permanent label also includes additional information about the IV solution, such as the concentration of the drug contained therein, the class of the drug contained therein, and / or a dosage guide for the drug contained therein. Typically, the IV container is suspended from an IV container support (e.g., an IV support pole), and the IV tubing is typically connected to and extends from the IV container to the patient.

[0005] Currently, there are two main types of IV containers on the market. One type involves semi-rigid bottles, and the other involves flexible bags.

[0006] The requirements for containers for such drugs (e.g., IV) are very high because they must ensure the general quality, particularly sterility, of the contained product during production and shelf life. Specifically, these requirements address the thermal stability, transparency, impact properties, and water and gas permeability of the container wall material.

[0007] To meet requirements for thermal stability, transparency, and impact resistance, semi-rigid bottles typically have sufficiently thick walls. Even with high optimization, a typical 500ml bottle can weigh up to 30g, including other components not formed from polymer films, such as closures and / or inlet ports and / or hangers.

[0008] Flexible bags are typically used as outer wraps in secondary packaging to meet water and gas permeability requirements. Therefore, for a 500ml solution content, a typical outer packaging system available on the market weighs approximately 27g (including the main bag, other components not formed of polymer film, i.e., the closure and / or entry port, and the outer packaging). Summary of the Invention

[0009] Sustainability is becoming increasingly important in all types of technology, including healthcare. A key aspect, especially in packaging, is reducing material consumption and recycling. Therefore, there is often a need for pharmaceuticals, particularly intravenous (IV) bags, that use less plastic material compared to containers known in the prior art.

[0010] When the membrane used to form the drug pouch is too thin, its gas-barrier properties decrease. In particular, water vapor permeability increases to a point where it becomes impossible to ensure that the concentrations of the various chemical components in the drug solution remain within acceptable limits for extended periods, thus shortening the shelf life of the product (preferably a pharmaceutical product) contained in the drug pouch. Furthermore, increased permeability of air and other gases through the primary membrane tends to allow gas ingress, resulting in an increase in the primary headspace, which in turn causes the drug pouch to swell. This result is undesirable because, for example, it increases the risk of injecting gas into the patient at the end of administration, and if the pouch is pressurized internally by excessive primary headspace, stress may also be applied to the material and the sealing areas between different components of the drug pouch (e.g., the membrane and port system). In extreme cases, the drug pouch may eventually fail, for example, by gradually delaminating or rupturing under pressure and leaking.

[0011] Therefore, the object of the present invention is to provide a bag for pharmaceutical applications that uses a membrane material that is reduced by at least 50 wt.% less than market standards, while maintaining a sufficiently high barrier to gas permeation without requiring an outer packaging. Market standards with similar shelf-life typically include a primary bag (i.e., a membrane) and an outer packaging. It has now been surprisingly discovered that this object can be achieved by a bag for pharmaceutical applications comprising a bag body enclosing a cavity, the bag body including at least one opening connecting the cavity to an ambient fluid, wherein the bag body includes a body wall comprising a membrane, characterized in that the membrane has a value equal to or less than 270 g / m³ as measured according to ISO 536:2019. 2 The membrane has a weight of grammage and a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in an annual increase in gas volume not exceeding 3% of the total volume of the bag cavity.

[0012] The advantage of this invention is that, unlike prior art drug bags which comprise two packaging layers—one for mechanical properties and another surrounding the first for barrier properties—this drug bag can be replaced by a single packaging layer that provides both mechanical and barrier properties. This reduces the amount of material used in the drug bag, and thus reduces weight and environmental impact. Furthermore, the production process of the drug bag according to this invention is simpler than that of the prior art because no additional packaging steps are required. Attached Figure Description

[0013] Figure 1 A schematic diagram showing the intake air development over time for comparative example CE1-3 is displayed.

[0014] Figure 2 A schematic diagram showing the water loss of comparative example CE1-3 over time is displayed.

[0015] Figure 3 A schematic diagram showing the intake airflow over time for comparative example CE1 and embodiment IE1-2 of the present invention is displayed.

[0016] Figure 4 A schematic diagram showing the water loss over time in comparative example CE1 and embodiment IE1-2 of the present invention is displayed.

[0017] definition

[0018] The term "sterile" as used refers to the state of an object having a significantly reduced number of bacteria and / or viruses on its surface to reduce the risk of infection. Specifically, the term "sterile" means having less than 10 -6 Bioload is the theoretical probability of a single live microorganism being present on or within a sterilization unit. Bioload can be measured, i.e., according to ISO 11737-1:2018.

[0019] As used herein, the term "sterilization" refers to a method of destroying all forms of living microorganisms from a substance. Since there is always a possibility that at least one microorganism will be present in such a procedure, the purpose of sterilization is to reduce the presence of any initially present microorganisms or other potential pathogens. Typically, sterilization is performed if the bioload of the material to be sterilized is below 10. -6Sterilization is then accepted. Bioburden can be measured, for example, according to ISO 11737-1:2018. Several methods can be used to achieve sterilization. In one sterilization process, the object is heated to at least 105°C, preferably 121°C, for a certain duration to achieve sterility. Therefore, the object should not deform due to the increased temperature in a way that hinders its intended use. Preferably, the heating step is carried out in an autoclave. In another sterilization process, the object is brought into contact with toxic gases (such as a mixture of ethylene oxide and carbon dioxide). Filtration methods are also used for sterilizing liquids, i.e., by using membrane filters, Seitz filters, and / or candle filters. Finally, sterilization can be achieved by indirect energy input to or onto the object, for example by ultrasound, ultraviolet light, and by high-energy particles (e.g., electrons, gamma rays, or X-rays).

[0020] As used in this article, the term "headspace" refers to the volume of gas contained within the bag.

[0021] As used herein, the term “liquid tight” refers to the mass of an object that serves as a barrier to a liquid (preferably a water-based liquid).

[0022] As used in this article, the term "fluid closure" refers to a previous fluid connection that has been tightly sealed by another liquid entity.

[0023] As used herein, the term "barrier layer" refers to a material that can slow down the oxygen permeation process. Preferably, it comprises, more preferably, a plastic barrier material, most preferably ethylene-vinyl alcohol (EVOH), or a metal oxide material, most preferably a silicon oxide layer or an aluminum oxide layer. Such a barrier layer typically requires a support or adhesive layer to adhere to the drug container wall material.

[0024] As used herein, the term "intake" refers to the increase in the volume of gas inside a container (also known as the main headspace) when exposed to ambient gases over a given period of time. This increase is caused by the difference between the amount of gas (e.g., air, oxygen, carbon dioxide, nitrogen) diffusing into the container through its walls (e.g., membranes or extruded blow molding bodies, port systems, etc.) and the amount of gas (e.g., water vapor) diffusing out of the container. Diffusion typically depends on the specific gas and / or mixtures thereof, the specific permeability of the container walls to the various gases (ultimately including barriers to selected gases) and their thickness, temperature, and the physical and / or chemical gradients of the various gases. Such gradients can be further influenced by the chemical properties of the drug solution being filled. Intake also depends on the outer surface of the container, such that flatter containers generally exhibit higher intake (i.e., an increase in the main headspace) relative to the initial headspace during manufacturing. If the container walls include barriers to a specific gas, the mixture of gases permeating into the container may not be ambient air, but rather a gas depleted from one or more of its constituent gases.

[0025] As used herein, the term "water loss" refers to the loss of water in a filled drug solution due to water vapor diffusing out of the bag through the bag walls (e.g., membrane or extruded blow molding body, port system, etc.).

[0026] As used herein, the term "drug container" refers to a container suitable for drug administration, preferably for delivering drugs and / or nutrients to a patient, and most preferably for delivering intravenous drugs and / or nutrients to a patient. Most preferably, the drug container is an intravenous (IV) container.

[0027] As used herein, the term "environment" refers to the space defined by the bag body, which is located outside the bag body, i.e., separated from the bag cavity by the bag body wall. Therefore, the term "opening that fluidly connects the bag cavity to the environment" refers to an opening in the body wall that allows fluid communication with the body cavity and the space defined by the body wall, which is separated from the body cavity by the body wall.

[0028] As used herein, the term "intravenous container" or "IV container" refers to a container suitable for filling and storing sterile fluids, wherein the IV container is suitable for administering the sterile fluids intravenously to a patient. IV containers are preferably selected from semi-rigid bottles (preferably prepared by a blow molding-fill-seal process) and flexible bags. Preferably, the material of the IV container comprises a polymer, preferably composed of a polymer. Preferably, the IV container meets the following requirements: the IV container preferably undergoes heat sterilization at 125°C for 20 minutes. The wall of the IV container preferably remains transparent (haze <30%) after sterilization. According to ISO 15747, for bags with a volume equal to or less than 500 ml, the IV container preferably resists a drop from a height of 1.0 m, and for bags with a volume in the range of 500 ml to 1000 ml, the IV container preferably resists a drop from a height of 0.75 m. The IV container preferably resists a positive gauge pressure of 50 kPa for at least 15 minutes. The IV container exhibits a water loss of less than 5%, preferably less than 3%, during its shelf life (24 months, preferably 36 months) at 25°C / 40%RH. The IV container also has an air intake of less than 10 ml during its shelf life (24 months, preferably 36 months) at 25°C / 40%RH. Preferably, the IV container is a flexible bag.

[0029] As used herein, the term "oxygen scavenger" refers to a compound suitable for binding with molecular oxygen from the surrounding atmosphere. This binding can occur physically or chemically. Preferably, the binding occurs chemically. Most preferably, the oxygen scavenger is an antioxidant.

[0030] As used herein, the term “standard conditions” refers to a temperature of 23±2°C and a relative humidity of 50±2%.

[0031] As used herein, the term “nominal volume” refers to the declared volume of a drug solution that, according to drug requirements, should be able to be drawn from the container at least during the product’s shelf life.

[0032] As used herein, the term "total volume" refers to the maximum volume that can be contained in a container (preferably a bag) when in equilibrium with ambient pressure. The total volume of the container is measured by filling it with water at 23 ± 2°C and zero gauge pressure, wherein water is filled into the bag without any pressure other than that provided by gravity until the bag is completely filled with water without any visible introduction of gas, wherein the volume of the bag cavity is the volume of water. The container should be determined after the sterilization process, as exposure to heat can deform the container and / or cause the materials in which it is constructed to shrink / become stressed.

[0033] As used herein, the term "main bag" refers to a bag whose walls are in direct contact with the compound inside the bag's interior. Detailed Implementation

[0034] As described above, the present invention provides a bag for pharmaceutical applications having a reduced membrane material content compared to market standards, preferably at least 50 wt.% less. It has now been surprisingly discovered that this objective can be achieved by a bag for pharmaceutical applications comprising a bag body enclosing a cavity, the bag body including at least one opening connecting the cavity to an ambient fluid, wherein the bag body includes a body wall comprising a membrane, characterized in that the membrane has a value equal to or less than 270 g / m³ as measured according to ISO 536:2019. 2 The membrane has a weight of grammage and a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in an annual increase in gas volume that does not exceed 3% of the total volume of the bag cavity.

[0035] Preferably, the drug bag according to the invention is an intravenous (IV) bag.

[0036] As described above, the pharmaceutical bag according to the invention ensures that only one packaging layer is required, thanks to the combination of lightweight polymer materials with desired barrier and mechanical properties. This further ensures that the packaging does not reach a certain weight per square meter, thus reducing environmental impact. Therefore, a second bag wrapping around the first bag is not necessary, thereby reducing the amount and weight of plastic material required for packaging and protecting the pharmaceutical solution.

[0037] Therefore, preferably, the medicine bag according to the invention is a main bag. In a preferred embodiment of the invention, the bag does not include an outer packaging, i.e., a secondary bag. In another preferred embodiment of the invention, the medicine bag according to the invention may include an auxiliary bag, wherein the auxiliary bag performs a different function than the main bag. Potential functions may be dust protection and / or ensuring the sterility or disinfection of the bag.

[0038] The membrane for the wall of a medicine bag according to the invention provides a balanced profile of barrier and mechanical properties. Therefore, preferably, the membrane of the medicine bag according to the invention has a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in a maximum annual air ingress into the bag not exceeding 6 cm. 3 Furthermore, preferably, the membrane of the drug bag according to the invention has a pressure equal to or less than 50 cm², as measured according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor) at 23±2°C and 0% relative humidity. 3 / (m 2The gas permeability (at atmospheric pressure). It should be understood that the total air intake of the drug bag according to the invention depends not only on the gas permeability characteristics of the membrane used, but also on the size of the bag. Drug bags with a larger nominal volume generally also have a lower surface area to volume ratio compared to flat bags with a smaller nominal volume, due to the substantially cylindrical shape of such larger drug bags. Therefore, if a drug bag with a lower volume is implemented, then at some volumes, the gas permeability measured according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor) at 23±2°C and 0% relative humidity is equal to or less than 50 cm². 3 / (m 2 A gas permeability of at least one atmosphere (at atmospheric pressure) will be insufficient to prevent unwanted gas ingress. Therefore, total gas ingress has already been defined above. Those skilled in the art will understand that, with a lower nominal volume of the drug container, a membrane with a lower gas permeability can also be implemented to achieve the required protection against total gas ingress.

[0039] Therefore, preferably, the surface-to-volume ratio of the cavity of the drug bag according to the present invention is not higher than 100 cm². 2 / ml, preferably not higher than 50cm 2 / ml, more preferably not higher than 10cm 2 / ml, and preferably not higher than 5cm 2 / ml. This ensures that the barrier properties of the membrane can be achieved using a wider variety of materials. Similarly, preferably, the cavity of the drug bag according to the invention has a nominal volume in the range of 20ml to 5000ml. If the volume is smaller than this range, the choice of materials for the membrane becomes limited. Typically, the nominal volume of drug bags for intravenous injection applications is no greater than 5000ml.

[0040] Sterilization can affect the barrier properties of the membrane in the drug bag according to the invention. Since sterilization requires harsh conditions, the materials may also vary slightly. Because barrier performance can be sensitive to such conditions, it is preferable to measure the permeability after the filled drug bag has been sterilized, preferably after the production of the filled drug bag according to the invention. In practice, gas inhalation is more significant during the storage period of the bag compared to the production and / or sterilization period, which typically lasts only a few hours, and the bag can be stored for up to several years.

[0041] The film of the drug bag according to the invention can be a single layer. However, preferably, in the drug bag according to the invention, the film is a multilayer film comprising at least two layers. This has the advantage that different materials with different properties, preferably different barrier properties and different mechanical properties can be used.

[0042] Preferably, the multilayer film of the medicine bag according to the invention includes a barrier layer. More preferably, the barrier layer is a gas barrier layer or a moisture barrier layer. Most preferably, the barrier layer is both a gas barrier layer and a moisture barrier layer. Furthermore, preferably, the multilayer film of the medicine bag according to the invention includes a support layer. Most preferably, the multilayer film of the medicine bag according to the invention includes both a barrier layer and a support layer.

[0043] The barrier layer of the membrane of the drug bag according to the invention preferably comprises a material with a high gas barrier, particularly a high barrier to air, water vapor, and / or oxygen. More preferably, the barrier layer of the membrane of the drug bag according to the invention comprises a material selected from the list of the following compositions, preferably composed of: ethylene-vinyl alcohol (EVOH), polyvinyl alcohol (PVOH), metal oxides (preferably silicon oxide (SiO2)). x ) or aluminum oxide (AlO x Polyamide (PA), cyclic polyolefins, polymer / clay nanocomposites, or mixtures thereof. Most preferably, the barrier layer is composed of a metal oxide, preferably silicon or aluminum oxide.

[0044] The support layer of the membrane in the drug pouch according to the invention preferably comprises a material with improved mechanical properties (e.g., impact resistance). Therefore, more preferably, the support layer of the drug pouch according to the invention comprises a polymer material, preferably composed of a polymer material, wherein the polymer material preferably comprises polyolefin (PO), more preferably polypropylene (PP), and most preferably oriented polypropylene (OPP), more preferably composed of polyolefin (PO), more preferably polypropylene (PP), and most preferably oriented polypropylene (OPP). It has been found that, in particular, oriented polypropylene produces the desired mechanical properties without requiring a high-thickness carrier handle.

[0045] The multilayer film of the drug bag according to the invention can be produced by any method known to those skilled in the art for producing multilayer films. Preferably, the multilayer film of the drug bag according to the invention is produced by co-extrusion or lamination. It should be understood that co-extrusion can be used if the layers to be co-extruded, preferably the barrier layer and the support layer, are both thermoplastic polymers. Thus, the two polymers are melted in an extruder and co-extruded into a film. Finally, preferably in the case of EVOH, a connecting layer is necessary for co-extrusion. In cases where at least one layer is not made of a thermoplastic material or the layer is deposited on a previously formed film (e.g., made of metal oxide), it is preferred that the multilayer film of the drug bag according to the invention is produced by lamination.

[0046] Preferably, the film of the drug bag according to the invention, more preferably a multilayer film, has an elongation at break of 400-800%, preferably 500-750%, and most preferably 520-720% as measured according to ISO 527-3:2018.

[0047] Furthermore, preferably, the film of the drug bag according to the invention, more preferably the multilayer film, has a tensile modulus in the range of 200 to 500 MPa, preferably 250 to 480 MPa, and most preferably 260 to 465 MPa as measured according to ISO 527-3:2018.

[0048] Preferably, the polymer material of the support layer has a glass transition temperature Ti of no more than 80°C, preferably no more than 60°C, more preferably no more than 40°C, and most preferably no more than 20°C, as measured according to ASTM D3418. g This ensures thermal stability, especially considering the sterilization conditions used. Therefore, when the barrier layer is also made of a polymer material, the polymer material of the barrier layer has a glass transition temperature Tg of no more than 80°C, preferably no more than 60°C, more preferably no more than 40°C, and most preferably no more than 20°C, as measured according to ASTM D3418. g .

[0049] Preferably, the membrane of the drug bag according to the invention comprises a gas scavenger, and more preferably an oxygen scavenger. This further reduces the oxygen permeability of the material. Even if the permeability is within a certain range, this embodiment can still affect the removal of oxygen (which would otherwise be introduced by the intake air) from the membrane. In this way, the amount of oxygen diffused into the container is reduced, which further reduces the possibility of oxidative degradation of the filled drug solution, thus increasing its shelf life.

[0050] Preferably, the amount of polyolefin (PO) in the film of the drug bag according to the invention is at least 65 wt.-% relative to the total weight of the film. More preferably, the amount of polypropylene (PP) in the film of the drug bag according to the invention is at least 90 wt.-%, more preferably at least 95 wt.-%, relative to the total weight of the film. Similarly, in an alternative preferred embodiment of the drug bag of the invention, the amount of polyethylene (PE) in the film is at least 90 wt.-%, more preferably at least 95 wt.-%, relative to the total weight of the film. The large amount of polyolefin, especially polypropylene, ensures improved mechanical properties, such as impact resistance.

[0051] It should be noted that the multilayer film of the drug bag according to the invention is not limited to only one barrier layer and only one support layer. In alternative embodiments of the drug bag according to the invention, the multilayer includes at least two support layers and / or at least two barrier layers.

[0052] However, preferably, the multilayer film of the drug pouch according to the invention further includes at least one sealing layer. Preferably, the sealing layer comprises polyolefin (PO), more preferably polypropylene (PP), and is preferably composed of polyolefin (PO). The sealing layer has the advantage of preventing stickiness that may be caused by the barrier layer.

[0053] Typically, the order of the support layer, barrier layer, and optional sealing layer in the multilayer film of the drug bag according to the invention is not fixed. However, preferably, the support layer is the outermost layer of the multilayer film of the drug bag according to the invention, relative to the position of the bag cavity. This has the advantage that the remaining portion of the multilayer film is protected by mechanical properties, particularly the impact properties of the support layer of the multilayer film.

[0054] Preferably, the sealing layer is the innermost layer of the multilayer film of the drug bag according to the invention, relative to the position of the bag cavity. This prevents interaction between the barrier layer and the filling liquid of the drug bag according to the invention. Furthermore, it enables the weldability of the layers to form the bag via the sealing layer.

[0055] In a preferred embodiment of the pharmaceutical bag according to the invention, the membrane has a strength equal to or less than 250 g / m³ as measured according to ISO 536:2019. 2 The weight is preferably equal to or less than 220 g / m³. 2 The weight is preferably equal to or less than 205 g / m³. 2 The optimal weight is equal to or less than 190 g / m³. 2 The lower the membrane basis weight, the better the sustainability of the drug bag according to the invention, because less material can be used.

[0056] The membrane of the drug bag according to the invention is particularly characterized by its barrier properties. These are affected by all layers, i.e., also by the sealing layer and the support layer in the multilayer membrane of the drug bag according to the invention. Therefore, the overall barrier performance of the membrane (preferably a multilayer membrane) of the drug bag according to the invention is relevant to the invention.

[0057] Therefore, preferably, in the pharmaceutical bag according to the invention, the membrane has a diameter of less than 50 cm², as measured according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor) at 23±2°C and 0% relative humidity. 3 / (m 2 The gas permeability (at atmospheric pressure) is preferably less than 10 cm. 3 / (m 2 The gas permeability (at atmospheric pressure) is preferably less than 2 cm. 3 / (m 2 The gas permeability (at atmospheric pressure) is less than 1 cm⁻¹, and preferably even less than 1 cm⁻¹. 3 / (m 2The gas permeability (at atmospheric pressure) is considered. A lower gas permeability means a lower likelihood of oxygen intake, which could react with compounds within the drug bag according to the invention. Furthermore, less air intake results in a lower increase in the volume of the first top space of the drug bag according to the invention. Finally, a lower gas permeability allows for the use of less material to achieve the membrane's barrier properties, again leading to improved sustainability of the drug bag according to the invention.

[0058] The bag according to any one of the preceding claims, wherein the water vapor permeability of the membrane is equal to or less than 5 g / (m²) 2 • day), preferably equal to or less than 3g / (m 2 • day), more preferably equal to or less than 2 g / (m 2 • day), or even more preferably equal to or less than 1 g / (m 2 (day), and most preferably equal to or less than 0.5 g / (m 2 • (days), measured at 38±2℃ and 90±2% relative humidity according to ASTM F1249 or ISO 15106-2.

[0059] Similarly, in the pharmaceutical bag according to the invention, after sterilization at a temperature equal to or higher than 105°C, preferably in the range of 105°C to 128°C, the values ​​of the physical properties at 23±2°C and 0% relative humidity, preferably the gas permeability measured according to Annex A (differential pressure method, using a pressure sensor) of ISO 15105-1:2007, and / or the vapor permeability at 38±2°C and 90±2% relative humidity, ASTM F1249 or ISO 15106-2, are within ±10% of the corresponding value before sterilization, preferably within ±5% of the corresponding value before sterilization, and most preferably within ±2% of the corresponding value before sterilization.

[0060] These barrier properties are particularly achieved when the thickness of the barrier layer is greater than 10 μm, preferably greater than 12 μm, and most preferably greater than 15 μm. If the thickness of the barrier layer is greater than 35 μm, the barrier properties generally no longer improve significantly.

[0061] Particularly preferably, if the material of the barrier layer is ethylene-vinyl alcohol (EVOH), the thickness of the barrier layer of the film of the drug bag according to the present invention is in the range of 25 μm to 25 μm.

[0062] Particularly preferred is if the material of the barrier layer is silicon dioxide (SiO2). x If the thickness of the barrier layer of the film in the drug bag according to the present invention is in the range of 10 μm to 15 μm.

[0063] Preferably,

[0064] As mentioned above, one requirement for drug bags is that the liquid inside the bag can be seen from the outside. Therefore, the film of the bag must maintain a certain degree of transparency. Thus, preferably, the film of the drug bag according to the invention has a haze value of less than 60%, more preferably less than 30%, more preferably less than 25%, and most preferably less than 15%, as measured according to ASTM D1003, Procedure B.

[0065] Typically, the medicine bag according to the invention is used in a hanging position to allow gravity to remove liquid from the bag and deliver it to the patient. Therefore, the medicine bag according to the invention preferably includes a suspension device. Preferred suspension devices are selected from a list including holes, hooks, magnets, adhesive portions, or ropes. Most preferably, the suspension device is at least a hole adapted to suspend the bag on a rod, preferably a reinforcing hole.

[0066] Preferably, the bag includes a portion designed for opening the bag before drug administration. Therefore, the drug bag according to the invention preferably has a temporarily closed opening. Preferably, the opening of the drug bag according to the invention includes at least one inlet port, wherein the inlet port is preferably selected from a list consisting of a drug administration port, a withdrawal port, and a drug port. More preferably, the drug bag according to the invention includes at least one drug administration port and at least one opening, said at least one opening may be selected from the withdrawal port and the drug port.

[0067] Preferably, the drug bag according to the invention is filled with a liquid and a gas, wherein the volume of the gas defines a first top space, and wherein the volume of the first top space is no more than 5% of the total volume of the bag cavity, preferably no more than 2%, and most preferably no more than 1%. More preferably, the liquid comprises an oxygen-sensitive material. Most preferably, the oxygen-sensitive material is a pharmaceutically active material. The lower the volume of the first top space, the less oxygen migration can occur from the first top space to the liquid, resulting in less degradation of the oxygen-sensitive material. Alternatively, the gas in the bag is an oxygen-deficient gas.

[0068] Although the medicine pouches according to the invention have been developed for use without secondary packaging, such secondary packaging, preferably outer packaging, is not necessarily excluded. However, the function of the secondary pouch should differ from that of the main pouch. One reason for adding such secondary packaging might be dust protection and / or ensuring the sterility or disinfection of the pouch.

[0069] Experimental Section

[0070] Measurement methods

[0071] a) Air intake

[0072] The intake air was measured according to the procedure described below. The headspace of the bag was measured at different time points during a defined time period. During this time period, the bag was maintained in a controlled gas atmosphere with controlled temperature and humidity. In the first step, the headspace of the bag was aspirated from the bag using a syringe, with the syringe needle inserted through the resealable elastomeric closure of the bag. The volume of gas extracted from the bag was recorded. In the second step, the headspace was reinserted into the bag for the next time point.

[0073] b) Water loss

[0074] Water loss was measured according to the procedure described below. The weight of the bag was measured at different time points within a defined time period. During this period, the bag was maintained in a controlled gas atmosphere with controlled temperature and humidity. The water loss between the two time points was calculated by dividing the difference in the corresponding weight measurements by the weight of the initial fill volume.

[0075] c) Gas permeability

[0076] Gas permeability was measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using pressure sensors). Measurements were performed using a VAC-V2 device from Labthink.

[0077] d) Oxygen transmission rate

[0078] Oxygen permeability has been measured according to ASTM F1927. The measurements were performed on an OxySense 8101e from Systech Illinois.

[0079] e) Water vapor transmission rate

[0080] Water vapor transmission rate was measured according to ASTM F3299. Measurements were performed using an AquaSense 7101 from Systech Illinois.

[0081] f) Elongation at break

[0082] The elongation at break of the film was measured according to ISO 527-3:2018 ("Plastics - Determination of tensile properties - Part 3: Test conditions for films and sheets").

[0083] Test samples were prepared by cutting the membrane into strips with dimensions of 15 mm wide and 150 mm long. Before testing, the samples were conditioned at 23 °C ± 2 °C and 50% ± 5% relative humidity for at least 24 h according to ISO 291:2008.

[0084] Tensile tests were performed using a general-purpose tensile testing machine equipped with pneumatic clamps. For flexible membranes, the crosshead speed was set to 50 mm / min, as specified. Elongation at break (%) was calculated as the ratio of elongation at the point of break to the initial gauge length (100 mm) multiplied by 100. At least five measurements were performed for each membrane sample, and the average value was reported.

[0085] g) Tensile modulus

[0086] The tensile modulus was determined according to ISO 527-3:2018 in conjunction with ISO 527-1:2019 ("Plastics - Determination of tensile properties - Part 1: General principles").

[0087] Test samples were cut from a membrane measuring 15 mm wide and 150 mm long. Before testing, the samples were conditioned for at least 24 hours under the same conditions specified for the elongation at break measurement (23 °C ± 2 °C, 50% ± 5% relative humidity).

[0088] Tests were performed using a general-purpose tensile testing machine at a crosshead speed of 1 mm / min in the initial linear portion of the stress-strain curve. The tensile modulus (MPa) was calculated from the slope of the stress-strain curve over a strain range of 0.05% to 0.25%, as specified in the standard. At least five independent measurements were performed for each sample, and the average value was reported.

[0089] For the membrane, measure the elongation at break and tensile modulus under the same conditions described above. Take care to ensure that the membrane orientation and layer structure are maintained during sample preparation and testing.

[0090] To ensure the integrity of the multilayer membrane during tensile testing, the clamping pressure was adjusted to prevent delamination while maintaining a firm contact. Measurements were taken along both the longitudinal (MD) and transverse (TD) directions to account for potential anisotropy introduced by the multilayer structure.

[0091] h) Membrane weight

[0092] The basis weight of the membrane has been measured using a scale according to ISO 536:2019.

[0093] Example

[0094] The following comparative examples illustrate the dependence of air intake and water loss on polymer films commonly used as gas barrier membranes in IV bags. Furthermore, embodiments of the invention are shown, illustrating a gas barrier layer according to the invention.

[0095] a) Materials

[0096] The following materials have been used in the embodiments of this application:

[0097] Membrane 1: A PP-based film with a thickness of 200 μm. Elongation at break is 798%, and tensile modulus is 59 MPa. This membrane has a g / m³ content of 180 g / m³. 2 The weight in grams.

[0098] Membrane 2: PP / EVOH / PP with a total thickness of 200 μm, exhibiting a viscosity of less than or equal to 0.2 cc / (m²) at 23℃ / 50% RH. 2 The oxygen permeability is *day*bar, and at 38℃ / 100%rH, it has less than or equal to 2.5g / (m³). 2 Water vapor transmission rate (per day). The thickness of the PP / EVOH / PP layers is 110μm / 30μm / 60μm. Elongation at break is 520%, and tensile modulus is 461 MPa. The membrane has a density of 202 g / m³. 2 The weight in grams.

[0099] Membrane 3: PET / SiO with a total thickness of 172 μm x / PP, at 23℃ / 50%rH, has a concentration of less than or equal to 1.5cc / (m 2 The oxygen permeability is *day*bar, and at 38℃ / 100%rH it is less than or equal to 4g / (m 2 Water vapor transmission rate per day (*). Layer PET-SiO x The PP thickness is 12μm / 160μm. The elongation at break is 720%, and the tensile modulus is 265 MPa. The membrane has a g / m³ content of 186 g / m³. 2 The weight in grams.

[0100] b) Comparative Examples CE1-3

[0101] Air intake has been measured over the shelf life of polyolefin-based membranes used in IV applications. Therefore, unpackaged bags made of PP-based membranes (membrane 1) were filled with WFI (water for spraying), and air intake was measured over time. The headspace present in the bags at the start of the test varied between CE1, CE2, and CE3. Measurements were taken for the bags as outlined in Table 1.

[0102] Table 1: Bags studied in CE1-3

[0103]

[0104] *Nominal volume

[0105] Figure 1The results of the air intake are shown. For a 500ml bag with a commonly used gas barrier, air intake can reach 100ml after a 3-year shelf life, while specifications typically require <20ml. The primary background of this instruction manual is to avoid any risk of gas entering the patient's bloodstream. Air intake originates from the sum of air intake via the administration line (approximately 15ml) and air intake via the bag's dead volume (approximately 5ml). To meet this specification at the end of the shelf life, the initial top space of the bag must be managed to be less than 10ml during the manufacturing process, and air intake must be maintained below 10ml.

[0106] Water loss in the CE1-3 bags was also measured. The results are reported in... Figure 2 The results show that currently typical primary membranes for IV applications (e.g., made from membrane 1) available on the market can be used without outer packaging, but only for large volumes (500ml and 1000ml). For smaller volumes, the water loss is slightly too high for the required shelf life.

[0107] Embodiments and Comparative Example 4 of the present invention

[0108] For the different membranes, air intake and water loss during the shelf life have been measured. Therefore, bags made from unpackaged membranes 1, 2, and 3 were filled with WFI, and air intake and water loss were measured over time. Measurements are as outlined in Table 2.

[0109] Table 2: Bags studied in CE4, IE1-3

[0110]

[0111] *Nominal volume

[0112] Embodiments of the present invention demonstrate that the barrier layer of the membrane has a significant impact on the air intake of the drug bag. Embodiments of the present invention allow specifications to be met at the end of the shelf life.

Claims

1. A bag for pharmaceutical application, comprising a bag body enclosing a bag cavity, the bag body including at least one opening fluidly connecting the bag cavity to the environment, wherein the bag body includes a body wall, wherein the body wall includes a membrane. Its features The membrane has a strength equal to or less than 270 g / m³ as measured according to ISO 536:2019. 2 The weight, and The membrane has a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in an annual increase in gas volume, said increase not exceeding 3% of the total volume of the bag cavity.

2. The bag according to claim 1, wherein the membrane has a gas permeability measured under standard conditions according to Annex A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor), resulting in a maximum air intake into the bag not exceeding 6 cm / s. 3 .

3. The bag according to claim 1 or 2, wherein the membrane has a pressure of less than 50 cm² as measured according to Appendix A of ISO 15105-1:2007 (differential pressure method, using a pressure sensor) at 23±2°C and 0% relative humidity. 3 / (m 2 The gas permeability (at atmospheric pressure) is preferably less than 10 cm. 3 / (m 2 The gas permeability (at atmospheric pressure) is preferably less than 2 cm. 3 / (m 2 The gas permeability (at atmospheric pressure) is preferably less than 1 cm. 3 / (m 2 Gas permeability (at atmospheric pressure).

4. The bag according to any one of claims 1 to 3, wherein the ratio of the surface area to the volume of the bag cavity is not higher than 10 cm². 2 / ml, preferably not higher than 5cm 2 / ml, and preferably not higher than 3cm 2 / ml.

5. The bag according to any one of claims 1 to 4, wherein the cavity of the bag has a volume in the range of 20 ml to 5000 ml.

6. The bag according to any one of claims 1 to 5, wherein the film is a multilayer film comprising a barrier layer and / or a support layer.

7. The bag according to claim 6, wherein the barrier layer comprises ethylene-vinyl alcohol (EVOH), polyvinyl alcohol (PVOH), metal oxide, preferably silicon dioxide (SiO2). x ) or aluminum oxide (AlO x Polyamide (PA), cyclic polyolefins, polymer / clay nanocomposites or mixtures thereof.

8. The bag according to claim 6 or 7, wherein the support layer comprises a polymer material, preferably polyolefin (PO), more preferably polypropylene (PP), and most preferably oriented polypropylene (OPP).

9. The bag according to any one of claims 6 to 8, wherein the support layer is the outermost layer relative to the location of the bag cavity.

10. The bag according to any one of claims 6 to 9, wherein the multilayer film comprises at least one sealing layer, wherein the sealing layer preferably comprises polyolefin (PO), preferably polypropylene (PP).

11. The bag of claim 10, wherein the sealing layer is the innermost layer relative to the location of the bag cavity.

12. The bag according to any one of claims 1 to 11, wherein the film has a strength equal to or less than 250 g / m³ as measured according to ISO 536:2019. 2 The weight is preferably equal to or less than 220 g / m³. 2 The weight is preferably equal to or less than 200 g / m³. 2 The weight, and preferably equal to or less than 180 g / m³. 2 The weight in grams.

13. The bag according to any one of claims 1 to 12, wherein the film has a haze of 60% or less, preferably 30% or less, as measured according to ASTM D1003 or ISO 14782.

14. The bag according to any one of claims 1 to 13, wherein the bag is filled with a liquid and a gas, wherein the volume of the gas defines a first top space, and wherein the volume of the top space is not greater than 5% of the total volume of the bag cavity, preferably not greater than 2%, and most preferably not greater than 1%.

15. The bag according to any one of claims 1 to 14, wherein the bag further comprises an outer packaging and wherein the volume between the outer packaging and the body wall defines a second top space.